Skip to main content
VRCA
NASDAQ Life Sciences

Record YCANTH Demand and a $27.5M Insider Credit Facility Extend Verrica's Cash Runway into 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.36
Mkt Cap
$92.078M
52W Low
$3.28
52W High
$9.821
52W Position info
63% above low
Off High info
45% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

VRCA sits 63% above its 52-week low of $3.28 on elevated volume (1.9× avg).

Summary

Record YCANTH demand in Q2 2026 and a $27.5M credit facility from its Chairman extend Verrica's cash runway into 2028, easing near-term liquidity concerns.


Key Events · Earnings and Guidance · VRCA

  • Record YCANTH Demand

    Dispensed applicator units reached 19,626 in Q2 2026, up 28.3% sequentially and 46.1% year-over-year, driving $5.1M in U.S. net product revenue.

  • $27.5M Insider Credit Facility

    Entered into a credit agreement with an entity controlled by Chairman Paul B. Manning for up to $27.5M, providing non-dilutive capital.

  • Cash Runway Extended into 2028

    Based on current operating plan and full availability of the new facility, cash runway could extend into 2028, mitigating near-term going concern risk.

  • Widening Net Loss

    Q2 2026 net loss was $13.2M ($0.62/share) vs. net income of $0.2M in Q2 2025, driven by higher R&D spend for the common warts Phase 3 program and a $1.7M legal settlement.


Analysis · VRCA · Life Sciences

Accelerating commercial traction for YCANTH is evident in the 28% sequential jump in dispensed units, yet the company remains deeply unprofitable with a $13.2M net loss. A new $27.5M credit facility from Chairman Paul Manning delivers non-dilutive capital that could push the cash runway into 2028, directly addressing the going concern risk flagged in the concurrent 10-Q. While this insider-backed financing is a strong survival signal, the path to profitability still hinges on sustained YCANTH growth and pipeline execution.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VRCA was trading at $5.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.1M. The 52-week trading range was $3.28 to $9.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VRCA - Latest Insights

VRCA
Nov 13, 2026, 7:53 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.87
Real-time Price: $3.10 info
Change: -$0.770 (-20%) info
Market Cap: $53.941M info
VRCA
Nov 12, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $3.10 info
Change: -$0.610 (-16%) info
Market Cap: $53.941M info
VRCA
Nov 12, 2026, 4:16 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.71
Real-time Price: $3.10 info
Change: -$0.610 (-16%) info
Market Cap: $53.941M info
VRCA
Aug 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.76
Real-time Price: $3.10 info
Change: -$1.66 (-35%) info
Market Cap: $53.941M info
VRCA
Aug 18, 2026, 5:00 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $4.68
Real-time Price: $3.10 info
Change: -$1.58 (-34%) info
Market Cap: $53.941M info